| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antigens, Helminth | 34 | 2024 | 190 | 4.600 |
Why?
|
| Helminth Proteins | 27 | 2024 | 101 | 3.390 |
Why?
|
| Trichinella spiralis | 20 | 2024 | 22 | 2.990 |
Why?
|
| Ancylostoma | 21 | 2018 | 98 | 2.480 |
Why?
|
| Ascariasis | 7 | 2021 | 73 | 2.190 |
Why?
|
| Protozoan Vaccines | 11 | 2021 | 96 | 1.850 |
Why?
|
| Necator americanus | 12 | 2018 | 91 | 1.540 |
Why?
|
| Vaccines | 13 | 2022 | 366 | 1.520 |
Why?
|
| Recombinant Proteins | 32 | 2023 | 1410 | 1.360 |
Why?
|
| Trichinellosis | 11 | 2024 | 14 | 1.350 |
Why?
|
| Antibodies, Helminth | 20 | 2021 | 125 | 1.280 |
Why?
|
| Ancylostomiasis | 14 | 2018 | 62 | 1.270 |
Why?
|
| Onchocerciasis | 4 | 2022 | 20 | 1.180 |
Why?
|
| Ascaris suum | 5 | 2021 | 32 | 1.150 |
Why?
|
| Mice, Inbred BALB C | 29 | 2023 | 1000 | 1.090 |
Why?
|
| Vaccines, Synthetic | 15 | 2022 | 316 | 1.030 |
Why?
|
| Chagas Disease | 8 | 2023 | 295 | 1.010 |
Why?
|
| Animals | 101 | 2024 | 34392 | 0.990 |
Why?
|
| Trypanosoma cruzi | 7 | 2023 | 236 | 0.990 |
Why?
|
| Adjuvants, Immunologic | 18 | 2022 | 382 | 0.950 |
Why?
|
| Cystatins | 5 | 2024 | 8 | 0.920 |
Why?
|
| Spike Glycoprotein, Coronavirus | 8 | 2023 | 187 | 0.860 |
Why?
|
| Filariasis | 3 | 2018 | 27 | 0.850 |
Why?
|
| Brugia malayi | 3 | 2018 | 40 | 0.840 |
Why?
|
| Vaccination | 18 | 2022 | 962 | 0.830 |
Why?
|
| Retinol-Binding Proteins | 3 | 2018 | 21 | 0.790 |
Why?
|
| Sepsis | 6 | 2023 | 482 | 0.780 |
Why?
|
| Immunoglobulin G | 14 | 2024 | 779 | 0.770 |
Why?
|
| Necatoriasis | 7 | 2018 | 37 | 0.770 |
Why?
|
| Trichuriasis | 3 | 2022 | 31 | 0.760 |
Why?
|
| Hookworm Infections | 6 | 2018 | 125 | 0.750 |
Why?
|
| Intestinal Volvulus | 1 | 2022 | 37 | 0.750 |
Why?
|
| Glutathione Transferase | 4 | 2013 | 156 | 0.750 |
Why?
|
| Immunodominant Epitopes | 3 | 2015 | 50 | 0.740 |
Why?
|
| Schistosoma japonicum | 4 | 2024 | 8 | 0.720 |
Why?
|
| Tropomyosin | 5 | 2020 | 26 | 0.710 |
Why?
|
| Complement C1q | 4 | 2024 | 19 | 0.680 |
Why?
|
| Amino Acid Sequence | 18 | 2021 | 2715 | 0.650 |
Why?
|
| Neglected Diseases | 2 | 2021 | 151 | 0.650 |
Why?
|
| Immunoglobulin E | 6 | 2021 | 160 | 0.640 |
Why?
|
| Immunization | 6 | 2022 | 308 | 0.630 |
Why?
|
| Toxocariasis | 2 | 2015 | 27 | 0.610 |
Why?
|
| Mice | 43 | 2024 | 17758 | 0.610 |
Why?
|
| Fatty Acid-Binding Proteins | 1 | 2018 | 30 | 0.600 |
Why?
|
| Parasitic Diseases | 1 | 2019 | 61 | 0.580 |
Why?
|
| Cloning, Molecular | 13 | 2021 | 897 | 0.560 |
Why?
|
| Gene Expression | 12 | 2021 | 1562 | 0.550 |
Why?
|
| Communicable Disease Control | 1 | 2019 | 138 | 0.550 |
Why?
|
| Antibodies, Protozoan | 9 | 2021 | 76 | 0.550 |
Why?
|
| Saccharomycetales | 6 | 2021 | 37 | 0.540 |
Why?
|
| Larva | 16 | 2019 | 248 | 0.500 |
Why?
|
| Toxocara canis | 1 | 2015 | 5 | 0.500 |
Why?
|
| Tissue Inhibitor of Metalloproteinases | 2 | 2008 | 22 | 0.500 |
Why?
|
| Cytokines | 16 | 2024 | 1289 | 0.480 |
Why?
|
| Molecular Sequence Data | 18 | 2015 | 3897 | 0.470 |
Why?
|
| Antigenic Variation | 1 | 2014 | 39 | 0.460 |
Why?
|
| Hypersensitivity | 4 | 2019 | 185 | 0.460 |
Why?
|
| Recombinant Fusion Proteins | 5 | 2023 | 772 | 0.460 |
Why?
|
| Dogs | 13 | 2018 | 775 | 0.440 |
Why?
|
| Disease Models, Animal | 18 | 2024 | 4416 | 0.440 |
Why?
|
| Salivary Proteins and Peptides | 3 | 2020 | 19 | 0.430 |
Why?
|
| Pichia | 10 | 2017 | 56 | 0.430 |
Why?
|
| Immune Evasion | 4 | 2024 | 35 | 0.430 |
Why?
|
| Onchocerca volvulus | 3 | 2019 | 15 | 0.410 |
Why?
|
| Dendritic Cells | 5 | 2019 | 414 | 0.400 |
Why?
|
| Basophils | 1 | 2012 | 10 | 0.400 |
Why?
|
| Histamine Release | 1 | 2012 | 10 | 0.400 |
Why?
|
| Calreticulin | 2 | 2024 | 20 | 0.400 |
Why?
|
| Immunoglobulin Fc Fragments | 1 | 2012 | 30 | 0.400 |
Why?
|
| Acute Lung Injury | 2 | 2024 | 63 | 0.380 |
Why?
|
| Leishmania | 2 | 2023 | 29 | 0.380 |
Why?
|
| Metalloendopeptidases | 5 | 2007 | 101 | 0.380 |
Why?
|
| Host-Parasite Interactions | 5 | 2019 | 72 | 0.370 |
Why?
|
| Helminths | 2 | 2022 | 48 | 0.370 |
Why?
|
| Vaccines, DNA | 3 | 2016 | 48 | 0.370 |
Why?
|
| Parasite Load | 7 | 2021 | 31 | 0.360 |
Why?
|
| Antibodies, Viral | 6 | 2024 | 1154 | 0.360 |
Why?
|
| Alum Compounds | 6 | 2022 | 41 | 0.360 |
Why?
|
| Cricetinae | 7 | 2018 | 422 | 0.350 |
Why?
|
| Anthelmintics | 3 | 2018 | 55 | 0.350 |
Why?
|
| CD4-Positive T-Lymphocytes | 5 | 2021 | 472 | 0.330 |
Why?
|
| Heme | 1 | 2010 | 52 | 0.320 |
Why?
|
| Antigens, Protozoan | 4 | 2021 | 66 | 0.320 |
Why?
|
| Chagas Cardiomyopathy | 3 | 2019 | 48 | 0.320 |
Why?
|
| DNA, Complementary | 6 | 2015 | 462 | 0.320 |
Why?
|
| Saccharomyces cerevisiae | 5 | 2023 | 427 | 0.310 |
Why?
|
| T-Lymphocytes, Regulatory | 4 | 2019 | 216 | 0.310 |
Why?
|
| Soil | 3 | 2021 | 57 | 0.310 |
Why?
|
| Trichuris | 3 | 2022 | 26 | 0.310 |
Why?
|
| Leishmaniasis Vaccines | 2 | 2020 | 20 | 0.310 |
Why?
|
| Th2 Cells | 6 | 2021 | 185 | 0.300 |
Why?
|
| Gerbillinae | 3 | 2018 | 55 | 0.300 |
Why?
|
| Programmed Cell Death 1 Receptor | 2 | 2020 | 128 | 0.300 |
Why?
|
| Female | 44 | 2024 | 67035 | 0.290 |
Why?
|
| Inflammation | 6 | 2023 | 1446 | 0.290 |
Why?
|
| Ancylostomatoidea | 3 | 2018 | 60 | 0.280 |
Why?
|
| Humans | 44 | 2024 | 125757 | 0.280 |
Why?
|
| China | 6 | 2019 | 246 | 0.280 |
Why?
|
| Variant Surface Glycoproteins, Trypanosoma | 2 | 2018 | 6 | 0.270 |
Why?
|
| DNA, Helminth | 2 | 2010 | 22 | 0.270 |
Why?
|
| Immunogenicity, Vaccine | 2 | 2019 | 106 | 0.270 |
Why?
|
| N-Glycosyl Hydrolases | 2 | 2016 | 14 | 0.260 |
Why?
|
| Psychodidae | 2 | 2017 | 14 | 0.260 |
Why?
|
| Leishmania donovani | 2 | 2016 | 23 | 0.260 |
Why?
|
| HSP70 Heat-Shock Proteins | 2 | 2018 | 70 | 0.260 |
Why?
|
| Colitis | 2 | 2020 | 151 | 0.250 |
Why?
|
| Cysteine Proteinase Inhibitors | 2 | 2017 | 40 | 0.250 |
Why?
|
| Hemeproteins | 1 | 2005 | 7 | 0.250 |
Why?
|
| Toll-Like Receptor 2 | 3 | 2023 | 56 | 0.250 |
Why?
|
| Hemolysin Proteins | 2 | 2018 | 30 | 0.250 |
Why?
|
| Lung | 7 | 2024 | 1496 | 0.250 |
Why?
|
| Protein Binding | 5 | 2024 | 1758 | 0.250 |
Why?
|
| Endotoxins | 2 | 2018 | 48 | 0.250 |
Why?
|
| Protozoan Proteins | 2 | 2016 | 111 | 0.250 |
Why?
|
| Malaria, Falciparum | 2 | 2022 | 46 | 0.240 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2016 | 823 | 0.240 |
Why?
|
| Plasmodium falciparum | 2 | 2022 | 64 | 0.230 |
Why?
|
| Paraquat | 1 | 2024 | 13 | 0.230 |
Why?
|
| Immunotherapy | 3 | 2018 | 681 | 0.230 |
Why?
|
| Carrier Proteins | 3 | 2015 | 1033 | 0.220 |
Why?
|
| Vaccines, Subunit | 5 | 2021 | 66 | 0.220 |
Why?
|
| Echinococcus granulosus | 1 | 2023 | 2 | 0.220 |
Why?
|
| CD8-Positive T-Lymphocytes | 4 | 2022 | 397 | 0.220 |
Why?
|
| Epitopes | 2 | 2016 | 433 | 0.220 |
Why?
|
| Leukocytes, Mononuclear | 3 | 2020 | 326 | 0.220 |
Why?
|
| Protein Domains | 5 | 2021 | 236 | 0.210 |
Why?
|
| Spleen | 4 | 2016 | 281 | 0.210 |
Why?
|
| Macrophages | 6 | 2024 | 627 | 0.210 |
Why?
|
| Sequence Alignment | 7 | 2017 | 619 | 0.210 |
Why?
|
| Leishmaniasis | 1 | 2023 | 34 | 0.210 |
Why?
|
| Parasites | 1 | 2023 | 34 | 0.200 |
Why?
|
| Dextran Sulfate | 2 | 2020 | 47 | 0.200 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 5 | 2008 | 1299 | 0.200 |
Why?
|
| Electron Transport Complex IV | 2 | 2001 | 39 | 0.200 |
Why?
|
| Onchocerca | 1 | 2022 | 5 | 0.200 |
Why?
|
| Ivermectin | 1 | 2022 | 7 | 0.200 |
Why?
|
| Gene Expression Regulation, Developmental | 3 | 2014 | 1011 | 0.190 |
Why?
|
| Mice, Inbred C57BL | 7 | 2023 | 4422 | 0.190 |
Why?
|
| Blindness | 1 | 2022 | 71 | 0.190 |
Why?
|
| Complement Pathway, Classical | 2 | 2024 | 4 | 0.180 |
Why?
|
| Immunoglobulin M | 2 | 2024 | 212 | 0.180 |
Why?
|
| Immunomodulation | 2 | 2018 | 79 | 0.180 |
Why?
|
| Neutrophils | 2 | 2020 | 381 | 0.180 |
Why?
|
| DNA, Kinetoplast | 1 | 2020 | 3 | 0.180 |
Why?
|
| Extracellular Traps | 1 | 2020 | 8 | 0.180 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2002 | 259 | 0.180 |
Why?
|
| Viral Vaccines | 2 | 2014 | 337 | 0.180 |
Why?
|
| Cattle | 1 | 2022 | 569 | 0.180 |
Why?
|
| Bodily Secretions | 1 | 2020 | 7 | 0.180 |
Why?
|
| Skin | 3 | 2012 | 519 | 0.180 |
Why?
|
| Th1 Cells | 5 | 2022 | 153 | 0.180 |
Why?
|
| Macrophages, Peritoneal | 1 | 2020 | 37 | 0.170 |
Why?
|
| Immunity | 2 | 2018 | 192 | 0.170 |
Why?
|
| Phlebotomus | 1 | 2020 | 17 | 0.170 |
Why?
|
| Leishmaniasis, Cutaneous | 2 | 2020 | 48 | 0.170 |
Why?
|
| Asthma | 2 | 2019 | 756 | 0.170 |
Why?
|
| Phylogeny | 3 | 2020 | 688 | 0.170 |
Why?
|
| Bacterial Proteins | 2 | 2018 | 888 | 0.170 |
Why?
|
| Insect Proteins | 1 | 2020 | 101 | 0.170 |
Why?
|
| Base Sequence | 6 | 2004 | 3110 | 0.170 |
Why?
|
| Cell Polarity | 1 | 2020 | 121 | 0.170 |
Why?
|
| Germinal Center | 1 | 2020 | 38 | 0.170 |
Why?
|
| Coinfection | 1 | 2021 | 172 | 0.160 |
Why?
|
| Epitopes, B-Lymphocyte | 1 | 2020 | 31 | 0.160 |
Why?
|
| Cysteine | 2 | 2017 | 139 | 0.160 |
Why?
|
| Sequence Homology, Amino Acid | 4 | 2015 | 658 | 0.160 |
Why?
|
| Tissue Extracts | 1 | 2019 | 13 | 0.160 |
Why?
|
| B-Lymphocytes | 2 | 2020 | 534 | 0.160 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2020 | 125 | 0.160 |
Why?
|
| Helminthiasis | 2 | 2021 | 79 | 0.160 |
Why?
|
| Circular Dichroism | 1 | 2018 | 86 | 0.150 |
Why?
|
| T-Lymphocytopenia, Idiopathic CD4-Positive | 1 | 2018 | 1 | 0.150 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2020 | 199 | 0.150 |
Why?
|
| Arthritis, Experimental | 1 | 2018 | 15 | 0.150 |
Why?
|
| Bacillus thuringiensis | 1 | 2018 | 1 | 0.150 |
Why?
|
| Protective Agents | 1 | 2018 | 35 | 0.150 |
Why?
|
| Respiratory Hypersensitivity | 1 | 2018 | 52 | 0.150 |
Why?
|
| Vitamin A | 1 | 2018 | 59 | 0.150 |
Why?
|
| Blotting, Western | 2 | 2015 | 1116 | 0.150 |
Why?
|
| Protein Structure, Secondary | 1 | 2018 | 238 | 0.150 |
Why?
|
| Milk Proteins | 1 | 2018 | 92 | 0.150 |
Why?
|
| Antibodies, Neutralizing | 4 | 2023 | 469 | 0.150 |
Why?
|
| Orthomyxoviridae Infections | 1 | 2018 | 59 | 0.140 |
Why?
|
| Interferon-gamma | 5 | 2019 | 505 | 0.140 |
Why?
|
| Mice, Inbred ICR | 4 | 2020 | 149 | 0.140 |
Why?
|
| Parasitemia | 4 | 2019 | 24 | 0.140 |
Why?
|
| Male | 22 | 2024 | 61813 | 0.140 |
Why?
|
| Superantigens | 1 | 2017 | 20 | 0.140 |
Why?
|
| Lymphocyte Activation | 1 | 2019 | 701 | 0.140 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2018 | 139 | 0.140 |
Why?
|
| Encephalomyelitis, Autoimmune, Experimental | 1 | 2016 | 35 | 0.130 |
Why?
|
| Myeloid Differentiation Factor 88 | 3 | 2023 | 85 | 0.130 |
Why?
|
| Salmonella typhimurium | 1 | 2016 | 43 | 0.130 |
Why?
|
| Immunoglobulin A | 3 | 2024 | 207 | 0.130 |
Why?
|
| Metalloproteases | 2 | 2007 | 15 | 0.130 |
Why?
|
| 14-3-3 Proteins | 1 | 2016 | 54 | 0.130 |
Why?
|
| Prevalence | 3 | 2019 | 2467 | 0.130 |
Why?
|
| Escherichia coli | 3 | 2015 | 985 | 0.130 |
Why?
|
| Myocardial Infarction | 1 | 2023 | 1050 | 0.130 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2017 | 164 | 0.130 |
Why?
|
| Lectins | 1 | 2015 | 54 | 0.120 |
Why?
|
| Mutant Proteins | 1 | 2016 | 114 | 0.120 |
Why?
|
| Parasite Egg Count | 5 | 2012 | 28 | 0.120 |
Why?
|
| Aging | 2 | 2018 | 1183 | 0.120 |
Why?
|
| Serologic Tests | 1 | 2015 | 118 | 0.120 |
Why?
|
| Cardiomyopathies | 1 | 2020 | 502 | 0.120 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2015 | 140 | 0.110 |
Why?
|
| Treatment Outcome | 7 | 2020 | 12425 | 0.110 |
Why?
|
| Endemic Diseases | 2 | 2024 | 57 | 0.110 |
Why?
|
| Middle East Respiratory Syndrome Coronavirus | 1 | 2014 | 22 | 0.110 |
Why?
|
| Genome, Helminth | 1 | 2014 | 10 | 0.110 |
Why?
|
| Immune Sera | 2 | 2004 | 95 | 0.110 |
Why?
|
| Immunization, Secondary | 1 | 2014 | 104 | 0.110 |
Why?
|
| Ascaris lumbricoides | 1 | 2014 | 19 | 0.110 |
Why?
|
| Immunity, Cellular | 3 | 2022 | 206 | 0.110 |
Why?
|
| Schistosomiasis mansoni | 1 | 2013 | 24 | 0.110 |
Why?
|
| Tetraspanins | 1 | 2013 | 30 | 0.110 |
Why?
|
| Crystallography, X-Ray | 3 | 2024 | 357 | 0.100 |
Why?
|
| Survival Analysis | 4 | 2018 | 1522 | 0.100 |
Why?
|
| Influenza Vaccines | 1 | 2018 | 481 | 0.100 |
Why?
|
| Molecular Weight | 3 | 2020 | 387 | 0.100 |
Why?
|
| Peptides | 2 | 2020 | 812 | 0.100 |
Why?
|
| RNA, Messenger | 3 | 2005 | 2832 | 0.100 |
Why?
|
| Complement Activation | 2 | 2024 | 52 | 0.100 |
Why?
|
| Mozambique | 2 | 2022 | 20 | 0.100 |
Why?
|
| Biological Products | 1 | 2014 | 122 | 0.100 |
Why?
|
| Molecular Docking Simulation | 2 | 2024 | 110 | 0.100 |
Why?
|
| Immunoglobulins | 1 | 2012 | 173 | 0.090 |
Why?
|
| Colon | 1 | 2014 | 351 | 0.090 |
Why?
|
| Administration, Intranasal | 2 | 2022 | 132 | 0.090 |
Why?
|
| Esophagus | 2 | 2011 | 221 | 0.090 |
Why?
|
| Mice, Knockout | 4 | 2020 | 3755 | 0.090 |
Why?
|
| Mice, Inbred AKR | 2 | 2022 | 14 | 0.090 |
Why?
|
| Mesocricetus | 3 | 2012 | 72 | 0.090 |
Why?
|
| Sensitivity and Specificity | 3 | 2020 | 2060 | 0.080 |
Why?
|
| Genetic Vectors | 3 | 2020 | 940 | 0.080 |
Why?
|
| Factor Xa Inhibitors | 1 | 2011 | 64 | 0.080 |
Why?
|
| Aluminum Hydroxide | 1 | 2010 | 41 | 0.080 |
Why?
|
| Lipid Peroxidation | 1 | 2010 | 97 | 0.080 |
Why?
|
| Open Reading Frames | 1 | 2010 | 211 | 0.080 |
Why?
|
| Mucous Membrane | 2 | 2022 | 89 | 0.080 |
Why?
|
| Lipopolysaccharides | 2 | 2023 | 297 | 0.080 |
Why?
|
| Binding Sites | 3 | 2018 | 1305 | 0.080 |
Why?
|
| Protein Conformation | 2 | 2024 | 836 | 0.080 |
Why?
|
| Matrix Metalloproteinases, Secreted | 1 | 2008 | 4 | 0.080 |
Why?
|
| Coronavirus Infections | 1 | 2014 | 361 | 0.080 |
Why?
|
| Ovalbumin | 2 | 2019 | 319 | 0.080 |
Why?
|
| Glutathione | 1 | 2010 | 196 | 0.080 |
Why?
|
| Interleukin-5 | 2 | 2018 | 43 | 0.070 |
Why?
|
| Viral Load | 2 | 2021 | 389 | 0.070 |
Why?
|
| Interleukin-4 | 2 | 2018 | 140 | 0.070 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 2 | 2012 | 309 | 0.070 |
Why?
|
| Species Specificity | 2 | 2014 | 551 | 0.070 |
Why?
|
| Dog Diseases | 2 | 2005 | 50 | 0.070 |
Why?
|
| Fatty Acids | 2 | 2015 | 343 | 0.070 |
Why?
|
| Gene Expression Regulation | 4 | 2018 | 2528 | 0.070 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 2012 | 344 | 0.070 |
Why?
|
| Immunologic Factors | 2 | 2020 | 174 | 0.070 |
Why?
|
| Interleukin-10 | 2 | 2018 | 174 | 0.070 |
Why?
|
| Monocytes | 2 | 2019 | 345 | 0.070 |
Why?
|
| Pandemics | 1 | 2014 | 1114 | 0.070 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 2 | 2018 | 80 | 0.060 |
Why?
|
| Intestines | 4 | 2004 | 577 | 0.060 |
Why?
|
| Histocompatibility Antigens Class II | 2 | 2018 | 84 | 0.060 |
Why?
|
| Connective Tissue | 1 | 2006 | 24 | 0.060 |
Why?
|
| Anticoagulants | 1 | 2011 | 594 | 0.060 |
Why?
|
| Forkhead Transcription Factors | 2 | 2019 | 359 | 0.060 |
Why?
|
| Herbicides | 1 | 2024 | 12 | 0.060 |
Why?
|
| Chromatography, Gel | 2 | 2016 | 95 | 0.060 |
Why?
|
| Myocardium | 2 | 2020 | 1025 | 0.060 |
Why?
|
| Antigens, Surface | 1 | 2004 | 117 | 0.060 |
Why?
|
| Cyst Fluid | 1 | 2023 | 6 | 0.060 |
Why?
|
| Seroepidemiologic Studies | 1 | 2024 | 122 | 0.060 |
Why?
|
| Africa | 1 | 2024 | 133 | 0.060 |
Why?
|
| Africa South of the Sahara | 1 | 2024 | 114 | 0.060 |
Why?
|
| Adult | 7 | 2024 | 29760 | 0.050 |
Why?
|
| Cysteine Endopeptidases | 1 | 2004 | 114 | 0.050 |
Why?
|
| Gene Library | 1 | 2004 | 218 | 0.050 |
Why?
|
| Malaria | 1 | 2024 | 87 | 0.050 |
Why?
|
| Vaccines, Combined | 1 | 2023 | 39 | 0.050 |
Why?
|
| DNA, Mitochondrial | 2 | 2001 | 211 | 0.050 |
Why?
|
| Antigens, CD | 2 | 2016 | 433 | 0.050 |
Why?
|
| Europe | 1 | 2024 | 357 | 0.050 |
Why?
|
| Immunohistochemistry | 2 | 2005 | 1712 | 0.050 |
Why?
|
| Caenorhabditis elegans | 2 | 2015 | 226 | 0.050 |
Why?
|
| Anemia | 1 | 2007 | 339 | 0.050 |
Why?
|
| Schistosoma | 1 | 2022 | 10 | 0.050 |
Why?
|
| Technology | 1 | 2023 | 63 | 0.050 |
Why?
|
| Reproducibility of Results | 2 | 2021 | 2906 | 0.050 |
Why?
|
| Immunization, Passive | 1 | 2022 | 120 | 0.050 |
Why?
|
| Immunity, Mucosal | 1 | 2022 | 87 | 0.050 |
Why?
|
| Cell Proliferation | 3 | 2016 | 2374 | 0.050 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 2001 | 289 | 0.050 |
Why?
|
| Heart | 2 | 2016 | 733 | 0.050 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2023 | 293 | 0.050 |
Why?
|
| Antibody Formation | 1 | 2022 | 266 | 0.050 |
Why?
|
| T-Lymphocytes | 2 | 2021 | 1728 | 0.040 |
Why?
|
| Administration, Inhalation | 1 | 2021 | 180 | 0.040 |
Why?
|
| RAW 264.7 Cells | 1 | 2020 | 40 | 0.040 |
Why?
|
| DNA, Protozoan | 1 | 2020 | 31 | 0.040 |
Why?
|
| Macrophage Activation | 1 | 2020 | 64 | 0.040 |
Why?
|
| Fermentation | 1 | 2020 | 66 | 0.040 |
Why?
|
| Specific Pathogen-Free Organisms | 1 | 2020 | 52 | 0.040 |
Why?
|
| Genetics, Population | 1 | 2001 | 188 | 0.040 |
Why?
|
| Gene Knockout Techniques | 1 | 2020 | 126 | 0.040 |
Why?
|
| Protein Stability | 1 | 2020 | 161 | 0.040 |
Why?
|
| Feces | 3 | 2012 | 726 | 0.040 |
Why?
|
| Macaca mulatta | 1 | 2021 | 491 | 0.040 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2020 | 264 | 0.040 |
Why?
|
| Adolescent | 5 | 2024 | 19477 | 0.040 |
Why?
|
| Autoimmunity | 1 | 2020 | 172 | 0.040 |
Why?
|
| Anti-Allergic Agents | 1 | 2019 | 27 | 0.040 |
Why?
|
| Immunity, Humoral | 1 | 2020 | 71 | 0.040 |
Why?
|
| Biomarkers | 2 | 2019 | 3098 | 0.040 |
Why?
|
| Protein Structure, Tertiary | 1 | 2021 | 768 | 0.040 |
Why?
|
| Chemokines | 1 | 2019 | 133 | 0.040 |
Why?
|
| Peptide Mapping | 1 | 2018 | 44 | 0.040 |
Why?
|
| Ascaris | 1 | 2018 | 10 | 0.040 |
Why?
|
| Ligands | 2 | 2015 | 539 | 0.040 |
Why?
|
| Young Adult | 2 | 2024 | 9119 | 0.040 |
Why?
|
| Rats | 3 | 2020 | 3728 | 0.040 |
Why?
|
| Swine Diseases | 1 | 2018 | 37 | 0.040 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2020 | 511 | 0.040 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2018 | 149 | 0.040 |
Why?
|
| Eosinophils | 1 | 2019 | 118 | 0.040 |
Why?
|
| Receptors, CXCR3 | 1 | 2018 | 21 | 0.040 |
Why?
|
| Receptors, CCR2 | 1 | 2018 | 26 | 0.040 |
Why?
|
| Interleukin-13 | 1 | 2018 | 97 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 1 | 2001 | 1592 | 0.040 |
Why?
|
| Intestinal Diseases, Parasitic | 1 | 2018 | 41 | 0.040 |
Why?
|
| Sequence Analysis | 1 | 2017 | 54 | 0.040 |
Why?
|
| Cholera Toxin | 1 | 2017 | 49 | 0.030 |
Why?
|
| Cecum | 1 | 2017 | 27 | 0.030 |
Why?
|
| Fibrosis | 1 | 2019 | 440 | 0.030 |
Why?
|
| Hydrolysis | 1 | 2017 | 161 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2018 | 587 | 0.030 |
Why?
|
| Drug Carriers | 1 | 2017 | 100 | 0.030 |
Why?
|
| Pyroglyphidae | 1 | 2016 | 9 | 0.030 |
Why?
|
| Integrin alpha Chains | 1 | 2016 | 16 | 0.030 |
Why?
|
| Receptors, CCR10 | 1 | 2016 | 1 | 0.030 |
Why?
|
| Receptors, CCR | 1 | 2016 | 2 | 0.030 |
Why?
|
| Th1-Th2 Balance | 1 | 2016 | 8 | 0.030 |
Why?
|
| Culture Media, Conditioned | 1 | 2016 | 81 | 0.030 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2017 | 130 | 0.030 |
Why?
|
| Transduction, Genetic | 1 | 2017 | 290 | 0.030 |
Why?
|
| Serine | 1 | 2017 | 175 | 0.030 |
Why?
|
| Complement C8 | 1 | 2015 | 1 | 0.030 |
Why?
|
| Complement C9 | 1 | 2015 | 3 | 0.030 |
Why?
|
| Vaccines, Attenuated | 1 | 2016 | 175 | 0.030 |
Why?
|
| Body Weight | 2 | 2014 | 990 | 0.030 |
Why?
|
| Cell Line | 1 | 2021 | 2762 | 0.030 |
Why?
|
| Dynamic Light Scattering | 1 | 2016 | 8 | 0.030 |
Why?
|
| Protein Isoforms | 1 | 2017 | 404 | 0.030 |
Why?
|
| Workflow | 1 | 2016 | 118 | 0.030 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 2016 | 135 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2002 | 1763 | 0.030 |
Why?
|
| Calcium-Binding Proteins | 1 | 2017 | 326 | 0.030 |
Why?
|
| Genes, Helminth | 1 | 2015 | 22 | 0.030 |
Why?
|
| Lipid A | 1 | 2015 | 23 | 0.030 |
Why?
|
| Hemolysis | 1 | 2015 | 112 | 0.030 |
Why?
|
| Protein Multimerization | 1 | 2016 | 128 | 0.030 |
Why?
|
| Crystallization | 1 | 2015 | 83 | 0.030 |
Why?
|
| Mutagenesis | 1 | 2016 | 346 | 0.030 |
Why?
|
| Child | 4 | 2022 | 24605 | 0.030 |
Why?
|
| Sus scrofa | 1 | 2015 | 129 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2017 | 420 | 0.030 |
Why?
|
| Swine | 1 | 2018 | 1209 | 0.030 |
Why?
|
| Erythrocytes | 1 | 2015 | 219 | 0.030 |
Why?
|
| Caenorhabditis elegans Proteins | 1 | 2015 | 88 | 0.030 |
Why?
|
| Equipment Design | 1 | 2016 | 599 | 0.030 |
Why?
|
| Adenoviridae | 1 | 2017 | 606 | 0.030 |
Why?
|
| Immunity, Innate | 1 | 2017 | 372 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2016 | 684 | 0.030 |
Why?
|
| Injections, Intraperitoneal | 1 | 2014 | 75 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2017 | 686 | 0.030 |
Why?
|
| Aged | 4 | 2024 | 19899 | 0.030 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2014 | 45 | 0.030 |
Why?
|
| Nitric Oxide | 1 | 2017 | 494 | 0.030 |
Why?
|
| Muscles | 1 | 2014 | 292 | 0.030 |
Why?
|
| Glycosylation | 1 | 2013 | 125 | 0.030 |
Why?
|
| Schistosoma mansoni | 1 | 2013 | 24 | 0.030 |
Why?
|
| Technology, Pharmaceutical | 1 | 2013 | 20 | 0.030 |
Why?
|
| Reproduction | 1 | 2015 | 237 | 0.030 |
Why?
|
| Nanoparticles | 1 | 2016 | 232 | 0.030 |
Why?
|
| Biotechnology | 1 | 2013 | 56 | 0.030 |
Why?
|
| Transcriptome | 1 | 2019 | 980 | 0.030 |
Why?
|
| Amino Acid Substitution | 1 | 2014 | 398 | 0.030 |
Why?
|
| Isoenzymes | 1 | 2013 | 232 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2019 | 1762 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2016 | 1084 | 0.020 |
Why?
|
| Viral Proteins | 1 | 2014 | 347 | 0.020 |
Why?
|
| Middle Aged | 4 | 2024 | 27003 | 0.020 |
Why?
|
| Lymphocytes | 1 | 2014 | 410 | 0.020 |
Why?
|
| Diarrhea | 1 | 2014 | 318 | 0.020 |
Why?
|
| Lymph Nodes | 1 | 2014 | 379 | 0.020 |
Why?
|
| Muscle, Skeletal | 1 | 2018 | 947 | 0.020 |
Why?
|
| Time Factors | 2 | 2016 | 6355 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2014 | 803 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2016 | 3063 | 0.020 |
Why?
|
| Blood Coagulation | 1 | 2011 | 125 | 0.020 |
Why?
|
| Child, Preschool | 2 | 2021 | 14137 | 0.020 |
Why?
|
| Global Health | 1 | 2014 | 567 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2007 | 461 | 0.020 |
Why?
|
| Immunoprecipitation | 1 | 2005 | 199 | 0.010 |
Why?
|
| Sex Ratio | 1 | 2004 | 11 | 0.010 |
Why?
|
| Hemoglobins | 1 | 2005 | 311 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2005 | 781 | 0.010 |
Why?
|
| Mutation | 1 | 2017 | 5909 | 0.010 |
Why?
|
| Brazil | 1 | 2003 | 123 | 0.010 |
Why?
|
| Conserved Sequence | 1 | 2004 | 291 | 0.010 |
Why?
|
| Gastrointestinal Tract | 1 | 2005 | 214 | 0.010 |
Why?
|
| Injections, Intramuscular | 1 | 2003 | 194 | 0.010 |
Why?
|
| Aged, 80 and over | 2 | 2005 | 6609 | 0.010 |
Why?
|
| DNA Primers | 1 | 2004 | 658 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2005 | 1243 | 0.010 |
Why?
|
| Pregnancy | 1 | 2014 | 7222 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2005 | 1106 | 0.010 |
Why?
|
| Haplotypes | 1 | 2001 | 522 | 0.010 |
Why?
|
| Research Design | 1 | 2003 | 695 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2003 | 1201 | 0.010 |
Why?
|
| Sex Factors | 1 | 2002 | 1288 | 0.010 |
Why?
|
| Radiation Injuries, Experimental | 1 | 1967 | 22 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2003 | 1707 | 0.010 |
Why?
|
| Age Factors | 1 | 2002 | 2833 | 0.010 |
Why?
|
| Diet | 1 | 1967 | 1140 | 0.010 |
Why?
|
| Risk Factors | 1 | 2002 | 10341 | 0.000 |
Why?
|
| Edible Grain | 1 | 1967 | 45 | 0.000 |
Why?
|
| Lactobacillus | 1 | 1967 | 45 | 0.000 |
Why?
|
| Enterobacteriaceae | 1 | 1967 | 35 | 0.000 |
Why?
|
| Meat | 1 | 1967 | 48 | 0.000 |
Why?
|
| Lactose | 1 | 1967 | 54 | 0.000 |
Why?
|